Upexi (NASDAQ:UPXI) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Upexi (NASDAQ:UPXI) has been given a **"sell (D-)" rating** by Weiss Ratings, despite some conflicting opinions from other analysts.
• Shares traded down to **$6.36**, with an average target price of **$15.50** from analysts, showing a potential upside despite current low stock performance.
• Insider transactions revealed that Director **Lawrence Dugan** bought 11,000 shares at an average price of **$5.69**, increasing his position by **10.85%**.

Upexi (NASDAQ:UPXI - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by research analysts at Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.

Several other research firms have also recently commented on UPXI. Cantor Fitzgerald upgraded shares of Upexi to a "strong-buy" rating in a report on Wednesday, August 13th. Alliance Global Partners began coverage on shares of Upexi in a research note on Monday, August 4th. They issued a "buy" rating and a $15.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Upexi currently has an average rating of "Moderate Buy" and a consensus target price of $15.50.

Upexi Stock Performance

Shares of UPXI stock traded down $0.13 during trading on Tuesday, hitting $6.36. 2,054,097 shares of the company were exchanged, compared to its average volume of 4,055,118. The business's 50-day simple moving average is $6.59 and its 200 day simple moving average is $7.20. Upexi has a twelve month low of $1.90 and a twelve month high of $22.57.

Insider Transactions at Upexi

In related news, Director Lawrence Dugan bought 11,000 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The shares were acquired at an average price of $5.69 per share, with a total value of $62,590.00. Following the completion of the transaction, the director owned 112,389 shares of the company's stock, valued at $639,493.41. The trade was a 10.85% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.42% of the company's stock.

Hedge Funds Weigh In On Upexi

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. North Star Investment Management Corp. bought a new stake in shares of Upexi in the 2nd quarter worth about $45,000. Millington Financial Advisors LLC acquired a new position in Upexi during the 2nd quarter worth about $60,000. XTX Topco Ltd acquired a new position in Upexi during the 2nd quarter worth about $249,000. Geode Capital Management LLC acquired a new position in Upexi during the 2nd quarter worth about $1,002,000. Finally, NewGen Asset Management Ltd acquired a new position in Upexi during the 2nd quarter worth about $1,720,000. Institutional investors own 5.68% of the company's stock.

About Upexi

Upexi, Inc manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc and changed its name to Upexi, Inc in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.